Objective-Deposits that accumulate beneath retinal pigment epithelium, called drusen, are early signs of age-related macular degeneration (AMD). We have shown that amyloid ␤ (A␤) is present in drusen, and A␤ may be involved in AMD development. We have also shown that endothelial progenitor cells (EPCs) may contribute to the development of choroidal neovascularization (CNV). Thus, the purpose of this study was to investigate the role played by CX3CR1, a chemokine receptor, in EPC migration and CNV formation. Methods and Results-EPCs collected from human umbilical cords were found to express higher levels of CX3CR1 than human umbilical vein endothelial cells, and exposure of EPCs to A␤ caused further upregulation of CX3CR1. This upregulation was decreased by blocking fractalkine, a ligand of CX3CR1. Exposure of EPCs to fractalkine increased their migration, but pretreatment with A␤ enhanced the migration. The fractalkine-induced EPC migration was more inhibited by EPCs derived from CX3CR1 Ϫ/Ϫ mice than wild-type mice. The area of laser-induced CNV was significantly smaller in wild-type mice that received bone marrow transplantation from CX3CR1 Ϫ/Ϫ mice than in those that received transplantation from wild-type mice. Conclusion-These data suggest that A␤ enhances EPC migration through the upregulation of CX3CR1. This upregulation might play a role in development of CNV. (Arterioscler Thromb Vasc Biol. 2011;31:e11-e18.)
A ge-related macular degeneration (AMD) is the leading cause of irreversible vision decrease in the elderly worldwide. [1] [2] [3] [4] The decrease of vision results from geographical atrophy or choroidal neovascularization (CNV) in the macula of the eye. During the development of CNV, new vessels develop from the choroidal vessels and penetrate the thick matrix of the Bruch membrane and pass into the avascular subretinal space.
Among the earliest signs of AMD are subretinal extracellular deposits, known as drusen, which accumulate beneath the retinal pigment epithelium (RPE). 5 Epidemiological studies have shown that the presence of many discrete or confluent drusen significantly increases the risk of developing CNV. 6, 7 We have found that amyloid ␤ (A␤) peptides are present in drusen, and we have suggested that their presence is the primary stimulus for the development of AMD. 8 The A␤ peptides vary in length from 39 to 43 amino acid residues and are produced by the sequential proteolytic processing of precursors of amyloid proteins. 9 Interestingly, A␤ is the main component of the senile plaques found in the brains of Alzheimer's patients. 9 -11 The results of our study on senescent neprilysin gene-disrupted mice that lack the A␤-degrading enzyme showed that there was a significant increase in the deposition of A␤ in the subretinal space. 8 This is relevant to this study because these mice developed several characteristics of human eyes at the early stage AMD, although they did not develop CNV spontaneously.
The exact mechanism of how CNV develop from drusen has not been determined. The results of recent studies have provided evidence that endothelial progenitor cells (EPCs) may be major contributors to the development of CNV. [12] [13] [14] [15] [16] [17] For example, experiments on laser-induced CNV in chimeric C57Bl/6 mice with bone marrow transplantation from green fluorescent protein-transgenic mice showed that 50% to 60% of the endothelial cells of the CNV were green fluorescent protein positive. 14 In addition, cells expressing the EPC marker AC133 were present in surgically excised CNV of human patients. 17 EPCs are considered to play significant roles in neovascularization elsewhere, such as in the hindlimb ischemia model in mice, by enhancing invasion of blood vessels into the matrix through the expression of protease cathepsin L. 18 EPCs were first described by Asahara et al in 1997, 19 and recent studies have shown that the capacity of EPCs to invade into the matrix was higher than that of mature endothelial cells. 18, 20 Basire et al 21 reported that EPCs express higher levels of urokinase-type plasminogen activator and its receptor than human umbilical vein endothelial cells (HUVECs). In addition, Urbich et al 18 reported that protease cathepsin L is expressed more strongly in EPCs than in mature endothelial cells, and cathepsin L is essential for matrix degradation and invasion by EPCs in vitro. We have recently shown that the cathepsin L expressed by EPCs is critical for the development of CNV in a mouse model of CNV. 22 The migration of EPCs into the subretinal space requires their mobilization from the bone marrow into the bloodstream and subsequent recruitment from the choroidal circulation into the subretinal space. Although the molecular pathways leading to the mobilization of EPCs from the bone marrow are not fully known, earlier studies demonstrated that several humoral factors, such as vascular endothelial growth factor, 23, 24 erythropoietin, 25 adiponectin, 23 and stromal cellderived factor-1␣ 26 trigger the release of EPCs. It is known that the factors that contribute to the recruitment of EPCs are different for different diseases. 27 CX3CR1 is a pertussis toxin-sensitive 7-transmembrane G protein-coupled receptor expressed on human natural killer cells, monocytes, Th1 CD4 ϩ cells, CD8 ϩ T cells, mast cells, 28 and lymphoid organ-derived endothelial cells. 29 Fractalkine, also designated CX3CL1, is the sole ligand of CX3CR1, 30 and the secreted form of fractalkine has potent chemotactic activity. You et al 31 reported that bovine retinal capillary endothelial cells express both fractalkine and CX3CR1. Immunostaining of human retinal tissue showed that the expression of fractalkine was strong in Müller glial cells, ganglion cells, and RPE. 32 In addition, an intravitreous injection of antifractalkine antibody decreased the retinal angiogenesis in the oxygen-induced retinopathy model, 31 suggesting that CX3CR1 and fractalkine play important roles in ocular angiogenesis.
Recent studies [33] [34] [35] [36] have shown an association between the sequence variation/expression of CX3CR1 and AMD. Combadière et al 34 demonstrated that retinal microglia express CX3CR1 and that an impairment of cell migration caused by CX3CR1 polymorphisms increases the risk of AMD. They suggested that the CX3CR1-dependent accumulation of subretinal microglia evoked cardinal features of AMD and also suggested a role of microglial cells in the pathogenesis of AMD. However, the role played by CX3CR1 in the migration of EPCs has not been examined.
Thus, the purpose of this study was to investigate what role CX3CR1 plays in the migration of EPCs and subsequent CNV formation.
Materials and Methods
EPCs were isolated from human cord blood or mouse abdominal artery blood. The expression of CX3CR1 was measured by immunocytochemistry, quantitative real-time polymerase chain reaction (PCR), and Western blot. EPC migration was examined using a modified Boyden chamber assay. Laser-induced CNV areas were compared between wild-type mice that received bone marrow transplantation from wild-type mice and those that received transplantation from CX3CR1 Ϫ/Ϫ mice. Total cell numbers of leukocytes and EPCs in abdominal artery blood were compared between wild-type mice and CX3CR1 Ϫ/Ϫ mice. The proliferative capacities of wild-type mice-and CX3CR1 Ϫ/Ϫ mice-derived EPCs were also examined. Detailed materials and methods are given in the Supplemental Data, available online at http://atvb.ahajournals.org.
Results

CX3CR1 Expression Is Constitutively Higher in EPCs Than in HUVECs
The results of PCR demonstrated that the mRNAs of fractalkine and CX3CR1 were constitutively expressed in EPCs and in HUVECs ( Figure 1 ). PCR also showed that the expression of the mRNA of CX3CR1 by EPCs was 46.7Ϯ6.5 times higher than its expression by HUVECs (Figure 2A ). Fluorescence microscopy revealed that the proteins of CX3CR1 were expressed in both EPCs and HUVECs ( Figure  2B ). Consistent with the PCR results, the fluorescence intensity of CX3CR1 was markedly higher in EPCs than in HUVECs ( Figure 2B ).
Exposure to A␤ 1-40 , Tumor Necrosis Factor-␣, Interleukin-1␤, and Fractalkine Upregulates CX3CR1 Expression in EPCs and HUVECs
Earlier studies showed that proinflammatory cytokines upregulate the CX3CR1 gene expression in HUVECs, 37 but there have been no reports of the expression and regulation of the CX3CR1 gene in EPCs. The PCR results showed that stimulation by A␤ 1-40 , tumor necrosis Real-time PCR to determine whether fractalkine and CX3CR1 are expressed in cultured human RPE cells, HUVECs, and EPCs. The cDNAs were synthesized from 2 g of total RNA, and the reaction products were subjected to PCR amplification (35 cycles) with specific primers for human fractalkine and CX3CR1. Product sizes of amplified products were 68 bp for fractalkine and 163 bp for CX3CR1. GAPDH was used as an internal control.
factor-␣ (TNF-␣), interleukin-1␤ (IL-1␤), or fractalkine induced a significant increase in the expression of CX3CR1 in HUVECs (Figure 2A ). However, the mRNA levels of the CX3CR1 gene in treated HUVECs were much lower than CX3CR1 mRNA levels of EPCs without any stimuli ( Figure 2A ). Also, A␤ 1-40 , TNF-␣, IL-1␤, and fractalkine caused a significant increase in the expression of CX3CR1 mRNA in EPCs ( Figure 3 ). Western blot analysis showed an increase in the synthesis of the CX3CR1 protein in human EPCs treated with A␤ 1-40 , TNF-␣, IL-1␤, or fractalkine compared with nontreated EPCs (Supplemental Figure I ).
Neutralization of TNF-␣, IL-1␤, and Fractalkine Partially Blocks A␤ 1-40 -Induced CX3CR1 Upregulation in EPCs
To determine whether the A␤ 1-40 -induced CX3CR1 upregulation in EPCs is regulated by TNF-␣, IL-1␤, or fractalkine, we examined the change in the level of the mRNA of CX3CR1 when EPCs were treated with neutralizing antibodies against TNF-␣, IL-1␤, or fractalkine by PCR. A␤ 1-40 induced a 2.66Ϯ0.05-fold increase of CX3CR1 mRNA expression compared with nontreated EPCs, whereas its reverse peptide A␤ 40 -1 (the same amino acids but in reverse sequence) had no effect ( Figure 3 ).
After confirming that the upregulation of CX3CR1 mRNA by TNF-␣, IL-1␤, or fractalkine was completely blocked by the addition of the neutralizing antibodies, we examined whether the neutralization of these factors affected the expression of the mRNA of CX3CR1 in EPCs. Neutralization of TNF-␣, IL-1␤, or fractalkine significantly reduced the A␤ 1-40 -induced upregulation of CX3CR1 mRNA to 1.87Ϯ0.11-fold, 2.09Ϯ0.08-fold, and 2.11Ϯ0.27-fold that of the nontreated control cells, respectively. Combined neutralization of TNF-␣, IL-1␤, or fractalkine significantly reduced A␤ 1-40 -induced CX3CR1 upregulation; however, it did not completely block the upregulation to the level of nontreated controls (still 1.45Ϯ0.12-fold that of nontreated control cells).
A␤ 1-40 Enhances Fractalkine-Induced Migration of EPCs
CX3CR1 has been shown to be associated with both the migration and adhesion of leukocytes in response to fractalkine. 28 Thus, the high expression of CX3CR1 in EPCs and the further upregulation by A␤ suggest the possibility that EPC migration may be mediated by CX3CR1. Cell migration analyses using Boyden chamber assays showed that fractalkine induced a migration of human EPCs in a dosedependent manner. The pretreatment of EPCs with A␤ 1-40 significantly enhanced fractalkine-induced migration of EPCs, whereas A␤ 40 -1 had no effect ( Figure 4A ). 
Fractalkine-Induced Cellular Migration Is Abolished in EPCs Derived From CX3CR1 ؊/؊ Mice
EPCs derived from CX3CR1 Ϫ/Ϫ mice and wild-type mice were also used in Boyden chamber assays to investigate the role of CX3CR1 in EPC migration. Our results showed that mouse recombinant fractalkine induced the migration of EPCs derived from wild-type mice in a dose-dependent manner, and pretreatment with A␤ 1-40 significantly enhanced the migration as shown in human EPCs. However, no obvious cell migration or enhancement of migration by A␤ pretreatment was detected in EPCs derived from CX3CR1 Ϫ/Ϫ mice even after stimulation by 200 ng/mL fractalkine ( Figure  4B ). In contrast, IL-1␤, another well-known stimulator of migration of monocytes, was capable of inducing migration of EPCs derived from both wild-type mice and CX3CR1 Ϫ/Ϫ mice (Supplemental Figure II) .
Transplantation of CX3CR1 ؊/؊ Mouse-Derived Bone Marrow Cells Inhibits CNV
To determine the contribution of CX3CR1 from bone marrowderived cells to the development of CNV, we transplanted bone marrow cells from CX3CR1 Ϫ/Ϫ mice or wild-type mice into wild-type mice as described. 22 One month after the transplantation, a laser-induced CNV was produced. Seven days after laser irradiation, the CNV area in wild-type mice that received bone marrow transplantation from CX3CR1 Ϫ/Ϫ mice was significantly smaller (1.44Ϯ0.23ϫ10 4 m 2 ) than that of wild-type mice that received a bone marrow transplantation from wildtype mice (8.84Ϯ1.36ϫ10 4 m 2 ; PϽ0.0001, Figure 5 and Supplemental Figure III ).
CX3CR1 Deficiency Does Not Affect Homing of Bone Marrow-Derived Cells
We compared the numbers of leukocytes and EPCs in wild-type and CX3CR1 Ϫ/Ϫ mice. The results showed that there was no significant difference in the number of leukocytes between CX3CR1 Ϫ/Ϫ mice (1.61Ϯ0.13ϫ10 7 /mL; nϭ3) and age-matched wild-type mice (1.55Ϯ0.30ϫ10 7 /mL; nϭ3; Pϭ0.753, Supplemental Figure IVA) . Also, there was no significant difference in the number of EPCs in the peripheral blood between CX3CR1 Ϫ/Ϫ mice (1272Ϯ280/mL; nϭ3) and wild-type mice (1363Ϯ532/mL; nϭ3; Pϭ0.8065, Supplemental Figure IVB ).
Fractalkine or A␤ 1-40 Does Not Affect Proliferation of EPCs
Finally, we examined whether A␤ 1-40 or fractalkine/ CX3CR1 signaling affected the proliferative potential of 
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EPCs (Supplemental Figure IVC) . There was no significant difference in the number of EPCs among nontreated cells (1153Ϯ245; nϭ3), fractalkine-treated cells (1151Ϯ274; nϭ3), A␤ 1-40 treated cells (1149Ϯ152; nϭ3), and cells treated with both A␤ 1-40 and fractalkine (1155Ϯ202; nϭ3).
Discussion
Our results showed that EPCs expressed levels of CX3CR1 that were 46.7 times higher than those of HUVECs, and exposure to A␤ 1-40 caused a further upregulation of CX3CR1 in EPCs. Because CX3CR1 is involved in the migration of various kinds of cells, including leukocytes, 28, 38 monocytes/ macrophages, 39 and lymphocytes, 40 we hypothesized that EPCs have a much higher potential to stimulate migratory activity than mature endothelial cells. In addition, we hypothesized that A␤ 1-40 will enhance this activity. To the best of our knowledge, a regulation of the CX3CR1 expression in EPCs has not been reported. The EPCs used in our study were early EPCs, which we characterized earlier. 41 These early EPCs expressed endothelial cell-specific markers, such as VE cadherin or CD31, and no previous studies have shown that they produce such high levels of CX3CR1. A recent study reported that late EPCs (or outgrowth endothelial cells [OECs]) also play a significant role in AMD. Thill et al 42 isolated OECs from peripheral blood of AMD patients, and they showed that patients with neovascular AMD had a 5.1-fold higher number of OECs than subjects without AMD.
To combine the results of the present study with those of Thill et al, 42 we believe that both early EPCs and OECs are important for the development of AMD, although they probably play different roles. The earlier studies had shown that proinflammatory cytokines, such as IL-1␤, IL-6, interferon-␥, and TNF-␣ are important modulators of CX3CR1 expression in various types of cells, 37, [43] [44] [45] [46] and the modulations take place through phosphatidylinositol 3-kinase and nuclear factor-B signaling pathways. 43 Among the proinflammatory cytokines, IL-1␤ and TNF-␣ have been shown to be present in human CNV tissues, 47, 34 and the results of this study showed that TNF-␣ and IL-1␤ upregulated the CX3CR1 expression in EPCs as reported in other cell types. 48, 49 In addition, fractalkine, the sole ligand of CX3CR1, upregulated the CX3CR1 expression in EPCs. There has not been an article that reported an upregulation of CX3CR1 by fractalkine in an autocrine manner in any type of cells; however, in light of the facts that Figure 4 . A, Effects of A␤ 1-40 pretreatment on fractalkinemediated migration of EPCs. Isolated EPCs that had been cultured in serum-free medium supplemented with or without A␤ 1-40 (25 mol/L) or A␤ 40 -1 (25 mol/L) for 16 hours were harvested, washed, resuspended in 1% fetal calf serum (FCS, HyClone, Utah) EBM-2 medium (2ϫ10 5 cell/mL suspensions). Cells were then placed on a polycarbonate membrane (8-m pore size) in a modified Boyden chamber and were exposed for 6 hours to migratory stimulus in the lower chamber (10 to 200 ng/mL of fractalkine supplemented with 1% FCS EBM-2 medium). At the end of treatment, cells on the lower part of the membrane were stained with hematoxylin and counted. Data represent meansϮSDs for duplicate samples (upper panel). Dotted line shows the migration of EPCs without pretreatment. The bold line shows the migration of EPCs that were pretreated with A␤ , and the thin line shows the migration of EPCs pretreated with A␤ 40 -1 . Each condition was examined at least 6 times, and the experiments were repeated at least 3 times. *PϽ0.05 vs nontreated EPCs. Lower panels show representative images of migrated cells in the Boyden chamber assay by fluorescence digital microscopy (KEYENCE VB6000, Olympus, Tokyo). Scale barsϭ500 m. B, Effects of A␤ pretreatment on fractalkine-induced cell migration in EPCs derived from CX3CR1 Ϫ/Ϫ mice and wild-type mice (WT). Isolated EPCs from CX3CR1 Ϫ/Ϫ mice and wild-type mice that had been cultured in serum-free medium supplemented with or without A␤ 1-40 (25 mol/L) or A␤ 40 -1 (25 mol/L) for 16 hours were harvested, washed, and resuspended in 1% FCS EBM-2 medium (2ϫ10 5 cell/mL suspensions). EPCs were then placed on a polycarbonate membrane (8-m pore size) in a modified Boyden chamber and were exposed for 6 hours to migratory stimulus in the lower chamber (10 to 200 ng/mL of fractalkine supplemented with 1% FCS EBM-2 medium). The thin line shows the migration of EPCs derived from CX3CR1 Ϫ/Ϫ mice that were pretreated with A␤ 40 -1 , and the thin dotted line shows the migration of EPCs from CX3CR1 Ϫ/Ϫ mice without pretreatment. The bold line shows the migration of EPCs from wild-type mice that were pretreated with A␤ 1-40 , and the bold dotted line shows the migration of EPCs from wild-type mice without pretreatment. Each condition was examined 6 times, and the experiments were repeated at least 3 times. *PϽ0.05 vs EPCs without A␤ 1-40 treatment. Lower panels show representative images of migrated cells in the Boyden chamber assay by fluorescence digital microscopy (KEYENCE VB6000). Scale barsϭ500 m. fractalkine activates nuclear factor-B signaling in smooth muscle cells 43, 50 and that TNF-␣ and IL-1␤ induced an upregulation of CX3CR1 in EPCs (Figure 3) , it is reasonable that fractalkine upregulates the CX3CR1 expression in EPCs. It is also possible that the fractalkine-induced upregulation of CX3CR1 in EPCs is through TNF-␣ or IL-1␤ produced by A␤ 1-40 -stimulated EPCs because EPCs produce TNF-␣ and IL-1␤ when stimulated by A␤ (data not shown). This autocrine mechanism might be a specific feature of endothelial cells because they are the only cell types that express both CX3CR1 and fractalkine (Figure 3) .
The A␤ 1-40 -induced upregulation of CX3CR1 in EPCs was significantly decreased by neutralizing antibodies against TNF-␣, IL-1␤, and fractalkine. This would indicate that the A␤ 1-40 -induced upregulation of CX3CR1 in EPCs is partly due to an autocrine mechanism that affects the release of cytokines or fractalkine from EPCs. However, even a combination of neutralizing antibodies against TNF-␣, IL-1␤, and fractalkine did not completely block the A␤ 1-40 -stimulated upregulation of CX3CR1 in EPCs. Thus, we suggest the possibility that some other mechanisms might also contribute to the A␤ 1-40 -induced upregulation of CX3CR1 in EPCs. This needs further investigation.
The results of the cell migration analyses showed that fractalkine induced EPC migration, and pretreatment of EPCs with A␤ 1-40 significantly enhanced the migration. However, fractalkine failed to induce the migration of EPCs derived from CX3CR1 Ϫ/Ϫ mice, and A␤ did not enhance fractalkineinduced migration of EPCs derived from CX3CR1 Ϫ/Ϫ mice ( Figure 4B ). These results suggest that CX3CR1 plays a critical role in EPC migration, and A␤ enhances the EPC migration through an upregulation of CX3CR1.
Macrophages and microglia have been observed in human CNV tissues, 34, 47 and Greaves et al 51 reported that macrophages express fractalkine. In addition, human RPE cells constitutively express the mRNA of fractalkine, and they also secret a soluble form of fractalkine as determined by ELISA (data not shown). The expression of fractalkine by the RPE cells was upregulated by TNF-␣ and IL-1␤ (data not shown). We recently showed that A␤ 1-40 increased the expression of TNF-␣ and IL-1␤ in macrophages and microglia. 52 Taken together, these findings suggest that macrophages/microglia, as well as cytokine-stimulated RPE cells, are the major cells that produce soluble fractalkine and attract EPCs to the subretinal space.
Finally, to clarify the role of CX3CR1 in EPCs in the development of CNV, we performed bone marrow transplantation experiments. Because CX3CR1 is expressed by some ocular microglia, 34 we transplanted bone marrow EPCs to eliminate the possibility that the effects were due to resident cells expressing CX3CR1. Thus, cells from CX3CR1 Ϫ/Ϫ mice whose bone marrow-derived cells lacked CX3CR1 were transplanted. The results showed that the CNV area was significantly smaller in wild-type mice that received bone marrow transplantation from CX3CR1 Ϫ/Ϫ mice than in wildtype mice that received bone marrow transplantation from wild-type mice. In the laser-induced CNV model, more than 65% of vascular endothelial cells within the CNV were of bone marrow origin. 14 Because neprilysin-deficient mice do not develop CNV despite the subretinal deposition of A␤, this mouse model was not used to examine the effect of bone marrow transplantation from CX3CR1 Ϫ/Ϫ mice.
There was no difference in the number of leukocytes and EPCs in the peripheral blood of CX3CR1 Ϫ/Ϫ mice and wild-type mice (Supplemental Figure IVA and IVB) . In addition, fractalkine or A␤ 1-40 did not induce a proliferation of EPCs (Supplemental Figure IVC) . Combining these data with the results of cell migration analysis that demonstrated that the fractalkine-induced EPC migration was lower in EPCs derived from CX3CR1 Ϫ/Ϫ mice than in EPCs derived from wild-type mice ( Figure 4B ), we suggest that the absence of CX3CR1 in bone marrow-derived EPCs reduced the CNV development. This was probably because of a reduction in the migration of EPCs to the subretinal space.
In conclusion, we have shown that EPCs constitutively express significantly higher levels of CX3CR1 than HUVECs, and A␤ causes a further upregulation of CX3CR1 in EPCs. Boyden chamber assays showed that fractalkine induces EPC migration in a dose-dependent manner, and A␤ enhances the fractalkine-induced migration of EPCs. In the laser-induced CNV model, the CNV area was significantly smaller in wild-type mice that received bone marrow transplantation from CX3CR1 Ϫ/Ϫ mice than in mice that received bone marrow transplantation from wild-type mice. Overall, our results suggest an important role for the A␤-regulated CX3CR1 in EPC migration and in subsequent CNV development. Thus, therapy targeting the fractalkine/CX3CR1 axis might be useful for treating the CNV in AMD.
